专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

101. 发明申请

WO2023288173A1 PHARMACEUTICAL COMPOSITIONS OF A B7-H3 ANTIBODY AND USE OF THE SAME 审中-公开
公开(公告)号：WO2023288173A1
公开(公告)日：2023-01-19
申请号：PCT/US2022/073462
申请日：2022-07-06
申请人： MACROGENICS, INC.
发明人： ZHOU, Yan , SAMPATHKUMAR, Krishnan , BURKE, Stephen, James , WANG, Xiaoyan
IPC分类号： A61K39/395 , A61K45/06 , A61P35/00
摘要： The present invention provides pharmaceutical compositions, for storage and administration, comprising an anti-human B7-H3 ("hB7-H3") antibody ("enoblituzumab") and buffering agents. The invention provides containers and kits comprising such pharmaceutical compositions. The invention further provides the use of such pharmaceutical compositions, containers, and kits containing enoblituzumab for the treatment of a cancer, and in certain aspects, treatment of a cancer expressing B7-H3.

102. 发明申请

WO2023283049A1 PHARMACEUTICAL COMPOSITIONS OF A PD-1 ANTIBODY AND USE OF THE SAME 审中-公开
公开(公告)号：WO2023283049A1
公开(公告)日：2023-01-12
申请号：PCT/US2022/034493
申请日：2022-06-22
申请人： MACROGENICS, INC.
发明人： SAMPATHKUMAR, Krishnan , ZHOU, Yan , BURKE, Stephen James
IPC分类号： A61K9/00 , A61K31/00 , A61K39/00 , A61K47/02 , A61K47/12 , A61K47/26
摘要： The present disclosure is provides pharmaceutical compositions, for storage and administration, comprising a human PD-1 ("hPD-1") antibody ("retifanlimab") and buffering agents. The disclosure further provides containers and kits comprising such pharmaceutical compositions. The disclosure further provides the use of such pharmaceutical compositions, containers, and kits containing retifanlimab in the treatment of a cancer, and in certain aspects treatment of a cancer expressing PD-L1.

103. 发明申请

WO2022026306A1 METHODS FOR THE USE OF A PD-1 X CTLA-4 BISPECIFIC MOLECULE 审中-公开
公开(公告)号：WO2022026306A1
公开(公告)日：2022-02-03
申请号：PCT/US2021/042901
申请日：2021-07-23
申请人： MACROGENICS, INC.
发明人： SUMROW, Bradley James , BONVINI, Ezio , SHARMA, Sharad , WIGGINTON, Jon Marc , BEREZHNOY, Alexey Yevgenyevich
IPC分类号： C07K16/30 , C07K16/28 , C07K16/46
摘要： The present invention is directed in part to dosing regimens for administering a PD-1 x CTLA- 4 bispecific molecule for the treatment of cancer, and other conditions. The invention is directed in part to the use of such molecules, and to the use of pharmaceutical compositions and pharmaceutical kits that contain such molecules and that facilitate the use of such dosing regimens in the treatment of cancer or to stimulate immune cells.

104. 发明申请

WO2019222104A1 OPTIMIZED GP41-BINDING MOLECULES AND USES THEREOF 审中-公开
公开(公告)号：WO2019222104A1
公开(公告)日：2019-11-21
申请号：PCT/US2019/032030
申请日：2019-05-13
申请人： MACROGENICS, INC. , DUKE UNIVERSITY
发明人： LAM, Chia-Ying, Kao , DIEDRICH, Gundo , NORDSTROM, Jeffrey, Lee , LIU, Liqin , JOHNSON, Leslie, S. , KOENIG, Scott , HAYNES, Barton, F. , FERRARI, Guido
IPC分类号： C07K16/10 , C07K16/28
摘要： The present invention is directed to optimized HIV-1 gp41-Binding Molecules having reduced immunogenicity. More specifically, the invention relates to optimized gp41-Binding Molecules that comprise a gp41-binding Variable Light Chain (VL) Domain and/or a gp41-binding Variable Heavy Chain (VH) Domain that has/have been optimized to reduce the immunogenicity of such Domain(s) upon administration to a recipient subject. The invention particularly pertains to gp41-Binding Molecules that are multispecific gp41-Binding Molecules (including bispecific diabodies (including DART® diabodies), BiTE®s, bispecific antibodies, trivalent binding molecules (including TRIDENT™ molecules), etc.) that comprise: (i) such optimized gp41-binding Variable Domain(s) and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that comprise any of such gp41-Binding Molecules, and to methods involving the use of any of such gp41-Binding Molecules in the treatment of HIV-1 infection.

105. 发明申请

WO2019050521A1 DOSING REGIMENS OF BI-SPECIFIC CD123 X CD3 DIABODIES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES 审中-公开
公开(公告)号：WO2019050521A1
公开(公告)日：2019-03-14
申请号：PCT/US2017/050471
申请日：2017-09-07
申请人： MACROGENICS, INC.
发明人： WIGGINTON, Jon, Marc , ALDERSON, Ralph, Froman , LECHLEIDER, Robert, Joseph
IPC分类号： A01N65/00
CPC分类号： C07K16/2866 , A61K38/00 , A61K2039/505 , A61K2039/545 , A61P35/00 , C07K16/2809 , C07K2317/31 , C07K2317/33 , C07K2317/73 , C07K2317/92
摘要： The present invention is directed to a dosing regimen for administering a CD123 x CD3 bi-specific monovalent diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such a regimen for the sequence-optimized CD 123 x CD3 bi-specific monovalent diabody "DART-A," that is capable of simultaneous binding to CD 123 and CD3.

106. 发明申请

WO2017214096A1 METHODS FOR THE USE OF CD32B X CD79B-BINDING MOLECULES IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS 审中-公开
标题翻译：使用CD32B X CD79B结合分子治疗炎性疾病和病症的方法
公开(公告)号：WO2017214096A1
公开(公告)日：2017-12-14
申请号：PCT/US2017/036079
申请日：2017-06-06
申请人： MACROGENICS, INC.
发明人： CHEN, Wei , MOORE, Paul, A. , PANDYA, Naimish, Bharat , BONVINI, Ezio
IPC分类号： C07K16/28 , C07K16/46
摘要： The present invention is directed to methods for using bispecific binding molecules that possess a binding site specific for an epitope of CD32B and a binding site specific for an epitope of CD79B, and are thus capable of simultaneous binding to CD32B and CD79B. The invention particularly concerns such molecules that are bispecific antibodies or bispecific diabodies (and especially such diabodies that additionally comprise an Fc Domain). The invention is directed to the use of such molecules, and to the use of pharmaceutical compositions that contain such molecules in the treatment of inflammatory diseases or conditions.
摘要翻译：本发明涉及使用具有对CD32B的表位特异的结合位点和对CD79B的表位特异性的结合位点的双特异性结合分子的方法，并且因此能够同时结合 CD32B和CD79B。本发明特别涉及这样的分子，其是双特异性抗体或双特异性双抗体（并且尤其是另外包含Fc结构域的此类双抗体）。本发明涉及这种分子的用途，以及含有这种分子的药物组合物在治疗炎性疾病或病症中的用途。

107. 发明申请

WO2017180813A1 NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF 审中-公开
标题翻译：新的B7-H3结合分子，抗体药物偶联物及其使用方法
公开(公告)号：WO2017180813A1
公开(公告)日：2017-10-19
申请号：PCT/US2017/027317
申请日：2017-04-13
申请人： MACROGENICS, INC.
发明人： LOO, Deryk, T. , HUANG, Ling , JOHNSON, Leslie, S. , SON, Thomas , SCRIBNER, Juniper , BONVINI, Ezio
IPC分类号： A61K39/395 , A61K47/68 , C07K16/28
摘要： The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention also particularly pertains to a molecule that comprises the human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety (a "B7-H3-ADC").
摘要翻译：本发明涉及能够结合人和非人B7-H3的新型B7-H3结合分子，特别是涉及与B7-H3交叉反应的分子非人灵长类动物（例如食蟹猴）。本发明另外涉及包含可变轻链和/或可变重链（VH）结构域的B7-H3结合分子，所述可变轻链和/或可变重链（VH）结构域已被人源化和/或去免疫化，以便在给予受体对象时表现出降低的免疫原性。本发明特别涉及双特异性，三特异性或多特异性B7-H3结合分子，包括双特异性双抗体，BiTE，双特异性抗体，三价结合分子等，其包含：（i）此类结合B7-H3的可变结构域和（ii）能够结合存在于效应细胞表面上的分子的表位的结构域。本发明还特别涉及包含与至少一个药物部分（“B7-H3-ADC”）缀合的人源化抗人B7-H3抗体的人B7-H3结合结构域的分子。

108. 发明申请

WO2017015433A3 COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF 审中-公开
标题翻译：化合物靶向IL-23A和B细胞活化因子（BAFF）及其用途
公开(公告)号：WO2017015433A3
公开(公告)日：2017-03-09
申请号：PCT/US2016043267
申请日：2016-07-21
申请人： BOEHRINGER INGELHEIM INT , MACROGENICS INC
发明人： SINGH SANJAYA , PAN QI , BARRETT RACHEL REBECCA , JOHNSON LESLIE S , GUPTA PANKAJ , LOW SARAH , WU HAIXIA
IPC分类号： A61K38/20 , A61K39/395 , C07K14/54 , C12N15/24
CPC分类号： C07K16/468 , A61K2039/505 , C07K16/241 , C07K16/244 , C07K16/2875 , C07K2317/31 , C07K2317/524 , C07K2317/53 , C07K2317/56 , C07K2317/60 , C07K2317/62 , C07K2317/76 , C07K2317/92
摘要： The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
摘要翻译：本公开涉及对IL23A和BAFF特异性的化合物，包含该化合物的组合物及其使用方法。还公开了与化合物和组合物相关的核酸，细胞和生产方法。

109. 发明申请

WO2016201051A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：治疗癌症的联合治疗
公开(公告)号：WO2016201051A1
公开(公告)日：2016-12-15
申请号：PCT/US2016/036608
申请日：2016-06-09
申请人： MACROGENICS, INC.
发明人： WIGGINGTON, Jon, Marc , PANDYA, Naimish, Bharat , LECHLEIDER, Robert, Joseph , KOENIG, Scott , BONVINI, Ezio
IPC分类号： A61K9/00 , A61K39/00 , A61K39/395
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2818 , C07K16/32 , C07K2317/24 , C07K2317/41 , C07K2317/524 , C07K2317/526 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要： This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.
摘要翻译：本发明涉及一种药物组合物，其包含特异性结合HER2 / neu的第一分子和特异性结合调节免疫检查点（或其配体）的细胞表面受体（或其配体）的第二分子。本发明特别涉及其中第二分子与PD-1结合的实施方案。本发明还涉及这种药物组合物用于治疗癌症和其它疾病的用途。

110. 发明申请

WO2015200119A1 COVALENTLY BONDED DIABODIES HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND METHODS OF USE THEREOF 审中-公开
标题翻译：具有PD-1和LAG-3的具有免疫反应性的双重结合的双歧杆菌及其使用方法
公开(公告)号：WO2015200119A1
公开(公告)日：2015-12-30
申请号：PCT/US2015/036634
申请日：2015-06-19
申请人： MACROGENICS, INC.
发明人： BONVINI, Ezio , JOHNSON, Leslie, S. , SHAH, Kalpana , LA MOTTE-MOHS, Ross , MOORE, Paul, A. , KOENIG, Scott
IPC分类号： C07K16/28
CPC分类号： C07K16/2803 , C07K16/2818 , C07K16/468 , C07K2317/31 , C07K2317/626 , C07K2317/74
摘要： The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a "PD-I x LAG-3 bi-specific diabody"). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a "PD-1 x LAG-3 bi-specific, tetra-valent diabody").
摘要翻译：本发明涉及包含两个或多个多肽链并且具有至少一个针对PD-1的表位具有免疫特异性的表位结合位点和至少一个对于一个或多个具有免疫特异性的表位结合位点的表位的双抗体 LAG-3表位（即，“PD-1×LAG-3双特异性双抗体”）。更优选地，本发明涉及包含四个多肽链并且具有对PD-1的一个或两个表位和两个表位结合位点具有免疫特异性的两个表位结合位点的双特异性双抗体，对于一个（或两个）LAG-3表位（即，“PD-1×LAG-3双特异性四价双抗体”）是免疫特异性的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式